MEDP

SEC source: 0001567619-22-017724 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,425,593

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $157.83 to $163.71. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017725 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,331,474

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $151.72 to $157.02. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017724 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,331,474

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $151.72 to $157.02. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017631 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,237,355

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $149.50 to $155.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017630 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,237,355

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $149.50 to $155.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017631 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,143,236

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $147.35 to $151.65. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017630 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,143,236

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $147.35 to $151.65. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017541 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,080,720

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $150.94 to $155.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017540 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,080,720

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $150.94 to $155.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017541 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 6,018,204

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $149.49 to $155.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017540 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,018,204

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $149.49 to $155.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017415 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,955,688

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $153.65 to $163.66. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017414 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,955,688

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $153.65 to $163.66. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017415 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,893,172

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $163.95 to $168.93. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017414 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,893,172

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $163.95 to $168.93. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017265 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,830,657

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $159.77 to $166.21. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017263 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,830,657

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $159.77 to $166.21. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017265 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,774,100

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $150.98 to $159.70. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017263 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,774,100

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $150.98 to $159.70. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017171 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,717,543

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $145.30 to $154.52. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017170 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,717,543

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $145.30 to $154.52. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017171 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,660,986

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.76 to $149.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017170 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,660,986

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.76 to $149.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017049 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,604,429

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, and amended on May 3, 2022.

F3 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.70 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017048 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,604,429

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, and amended on May 3, 2022.

F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.70 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-017049 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,555,715

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, and amended on May 3, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $143.20 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-017048 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,555,715

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, and amended on May 3, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $143.20 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-014239 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,513,639

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, and amended on May 3, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.885 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-014238 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,513,639

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, and amended on May 3, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $144.885 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-014112 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,505,309

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, and amended on May 3, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $142.97 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-014111 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,505,309

F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2022, and amended on May 3, 2022.

F2 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $142.97 to $145.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-011617 · doc1.xml · derivative · entry 2

DAVENPORT FRED B JR · CIK 0001181154 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,903

Underlying: Common Stock · 1,903 shares

Expires 2029-05-20

F2 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-22-011620 · doc1.xml · derivative · entry 1

Carley Brian T · CIK 0001677791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,903

Underlying: Common Stock · 1,903 shares

Expires 2029-05-20

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-22-011619 · doc1.xml · derivative · entry 1

Kraft Robert O. · CIK 0001558592 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,903

Underlying: Common Stock · 1,903 shares

Expires 2029-05-20

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-22-011618 · doc1.xml · derivative · entry 1

McCarthy Cornelius P. III · CIK 0001750355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,903

Underlying: Common Stock · 1,903 shares

Expires 2029-05-20

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-22-011616 · doc1.xml · derivative · entry 1

Keating Ashley M. · CIK 0001777217 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,903

Underlying: Common Stock · 1,903 shares

Expires 2029-05-20

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-22-011615 · doc1.xml · derivative · entry 2

King Tom C · CIK 0001792446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,903

Underlying: Common Stock · 1,903 shares

Expires 2029-05-20

F1 · derivative.exercise_date: The option vests on the earlier of (i) the day immediately preceding the date of the first annual meeting of the Issuer following the date of grant, and (ii) the first anniversary of the date of grant, subject to continued service on the board of directors of the Issuer through the vesting date.

SEC source: 0001567619-22-009930 · doc1.xml · derivative · entry 2

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 1,000 shares

Expires 2025-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested on February 28, 2022.

SEC source: 0001567619-22-009930 · doc1.xml · nonDerivative · entry 1

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-006231 · doc1.xml · derivative · entry 3

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2024-08-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested on August 5, 2019.

SEC source: 0001567619-22-006231 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 806,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-005628 · doc1.xml · derivative · entry 2

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,400 shares

Expires 2024-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested on March 15, 2021.

SEC source: 0001567619-22-005628 · doc1.xml · nonDerivative · entry 1

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,183

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-005254 · doc1.xml · nonDerivative · entry 1

DAVENPORT FRED B JR · CIK 0001181154 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,000

F1 · ownership.nature: Owned by trust for the benefit of the Reporting Person.

SEC source: 0001567619-22-004866 · doc1.xml · derivative · entry 2

Brady Kevin M. · CIK 0001877121 · CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,803

Underlying: Common Stock · 13,803 shares

Expires 2027-08-15

F1 · derivative.exercise_date: The option vests on the fourth anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries.

SEC source: 0001567619-22-004864 · doc1.xml · derivative · entry 2

EWALD STEPHEN P · CIK 0001677297 · General Counsel & Corp. Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,349

Underlying: Common Stock · 23,349 shares

Expires 2027-08-15

F1 · derivative.exercise_date: The option vests on the fourth anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries.

SEC source: 0001567619-22-004862 · doc1.xml · derivative · entry 2

GEIGER JESSE J · CIK 0001677399 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,707

Underlying: Common Stock · 31,707 shares

Expires 2027-08-15

F1 · derivative.exercise_date: The option vests on the fourth anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries.

SEC source: 0001567619-22-004861 · doc1.xml · derivative · entry 2

BURWIG SUSAN E · CIK 0001677418 · Exec. VP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,060

Underlying: Common Stock · 34,060 shares

Expires 2029-08-15

F1 · derivative.exercise_date: The option vests on the second anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries.

SEC source: 0001567619-22-004860 · doc1.xml · derivative · entry 3

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,174

Underlying: Common Stock · 93,174 shares

Expires 2029-08-15

F2 · derivative.exercise_date: The option vests on the second anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer or one of its subsidiaries.

SEC source: 0001567619-22-000730 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,483,019

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $216.175. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.